Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

568 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Ipilimumab in a real-world population: A prospective Phase IV trial with long-term follow-up.
Aamdal E, Jacobsen KD, Straume O, Kersten C, Herlofsen O, Karlsen J, Hussain I, Amundsen A, Dalhaug A, Nyakas M, Schuster C, Hagene KT, Holmsen K, Russnes HG, Skovlund E, Kaasa S, Aamdal S, Kyte JA, Guren TK. Aamdal E, et al. Among authors: kaasa s. Int J Cancer. 2022 Jan 1;150(1):100-111. doi: 10.1002/ijc.33768. Epub 2021 Sep 9. Int J Cancer. 2022. PMID: 34449877 Free article. Clinical Trial.
Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up.
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Hatlevoll R, Dahle R, Boye N, Wang M, Vigander T, Vilsvik J, Skovlund E, Hannisdal E, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Among authors: kaasa s. J Clin Oncol. 2002 Dec 15;20(24):4665-72. doi: 10.1200/JCO.2002.12.111. J Clin Oncol. 2002. PMID: 12488411 Clinical Trial.
Hypofractionated palliative radiotherapy (17 Gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: a national phase III trial.
Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S. Sundstrøm S, et al. Among authors: kaasa s. J Clin Oncol. 2004 Mar 1;22(5):801-10. doi: 10.1200/JCO.2004.06.123. J Clin Oncol. 2004. PMID: 14990635 Clinical Trial.
Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen).
Sundstrøm S, Bremnes RM, Kaasa S, Aasebø U, Aamdal S; Norwegian Lung Cancer Study Group. Sundstrøm S, et al. Among authors: kaasa s. Lung Cancer. 2005 May;48(2):251-61. doi: 10.1016/j.lungcan.2004.10.016. Epub 2004 Dec 15. Lung Cancer. 2005. PMID: 15829326 Clinical Trial.
Physical rehabilitation in patients with head and neck cancer: Impact on health-related quality of life and suitability of a post-treatment program.
Sandmæl JA, Bye A, Solheim TS, Balstad TR, Thorsen L, Skovlund E, Kaasa S, Lund JÅ, Oldervoll L. Sandmæl JA, et al. Among authors: kaasa s. Laryngoscope Investig Otolaryngol. 2020 Mar 17;5(2):330-338. doi: 10.1002/lio2.368. eCollection 2020 Apr. Laryngoscope Investig Otolaryngol. 2020. PMID: 32337365 Free PMC article.
568 results